Compare Boston Scientific Corporation (BSX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Williams-Sonoma, Inc. — how do they compare? Boston Scientific Corporation trades at $52.92 (market cap $74.52B), while Williams-Sonoma, Inc. trades at $240.47 (market cap $28.87B). The key difference: Boston Scientific Corporation is far larger — about 2.6× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.24% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | WSM | |
|---|---|---|
Market Cap | $74.52B | $28.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $251.81 |
52-Week Low | $42.63 | $168.64 |
Enterprise Value | $86.60B | $29.71B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.69, up 0.98% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and revenue growth to $20.07B in 2025, alongside improving net income margins. Analyst sentiment is overwhelmingly positive with 86% buy ratings and a $67.21 consensus price target, though recent news highlights guidance cuts and competitive pressures in key segments like WATCHMAN.
The stock presents a compelling long-term opportunity given robust earnings growth and institutional confidence, but faces near-term risks from execution challenges and market volatility. Upside potential exists if the company stabilizes guidance and leverages new product catalysts, making it attractive for investors with a tolerance for sector-specific headwinds.
Williams-Sonoma (WSM) trades at $242.44, down 3.25% on the day, showing strong profitability with 13.81% net margins and consistent earnings beats. The stock maintains bullish technical signals with support at $242 and resistance at $247. Recent news highlights executive stock sales and ongoing investor interest amid market volatility.
WSM offers solid fundamentals with high ROE (54.01%) and stable revenue near $7.7B, but faces valuation concerns with P/E of 27.48 above sector averages. Analyst consensus is mixed with 30% buy ratings and $231 price target below current levels, suggesting cautious optimism amid competitive retail pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
